Month: August 2023

Reported statistically significant reductions in plasma neurofilament light chain (NfL) levels compared to placebo at 24 weeks (p=0.04) in patients treated with CNM-Au8® in the HEALEY ALS Platform trial Announced publication of the results of the Phase 2 RESCUE ALS study and its open-label extension in the Lancet journal, eClinicalMedicine Received one-year grant from the National Multiple Sclerosis Society (NMSS) that will fund Cohort 2 of REPAIR-MS, a Phase 2 clinical study investigating target engagement of CNM-Au8 in patients with non-active progressive MS Company expects multiple near-term data announcements that will further support benefit and safety of CNM-Au8 in people living with ALS Company is preparing for upcoming ALS regulatory discussions with FDA Cash, cash equivalents and marketable securities of $49.2 million as of...

– Revenue Grew 30% Year-over-Year to $18.3 Million – – Increased Originations Capital Deployment by 88% Year-over-Year to $59.7 Million – – Net Income Increased 40% Year-over-Year to $6.4 Million – – Adjusted EBITDA Grew 33% Year-over-Year to $8.8 Million – ORLANDO, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) — Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a leading buyer of life insurance policies and vertically integrated alternative asset manager specializing in specialty insurance products, today reported results for the second quarter ended June 30, 2023. “Our strong second quarter results continue to validate Abacus’ differentiated business model and further contribute to our long track record of sustainable and profitable growth,” said Jay Jackson, Chief Executive...

Merger with Notable expected to close in late September or October, subject to VBL’s S-4 registration statement being declared effective and shareholder approval $24.3 million in cash and cash equivalents as of June 30, 2023 MODI’IN, Israel and NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update. “We continue to make good progress towards the closing of our previously announced merger with Notable,” said Prof. Dror Harats, M.D., Chief Executive Officer of VBL. “We believe the proposed merger represents the best path forward for the shareholders of both companies and for patients. The combined organization is expected to be listed on Nasdaq, and will apply Notable’s Predictive Precision Medicines...

Revenues and Adjusted EBITDARevenues and Adjusted EBITDAAdjusted Net Earnings and Free Cash Flow TTMAdjusted Net Earnings and Free Cash Flow TTMSugar Volume Variance and Sugar VolumesSugar Volume Variance and Sugar VolumesSugar Volume Variance and Sugar VolumesSugar Volume Variance and Sugar VolumesAdjusted Gross MarginAdjusted Gross MarginMaple Volumes and Adjusted Gross MarginMaple Volumes and Adjusted Gross MarginFree Cash FlowFree Cash FlowVANCOUVER, British Columbia, Aug. 14, 2023 (GLOBE NEWSWIRE) — Rogers Sugar Inc. (“our,” “we”, “us” or “Rogers”) (TSX: RSI) today reported third quarter of fiscal 2023 results with consolidated adjusted EBITDA of $23.8 million and $82.3 million for the current quarter and the first nine months of the year, respectively. “Our business...

Enrollment and dosing ongoing in registrational study of SerpinPC for the treatment of hemophilia BEnrollment and dosing ongoing in Phase 1/2a Study of LB101, a PD-L1xCD47 LockBody® for the treatment of solid tumorsIND-enabling activities advancing for ORX750, an oral selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; Announces ORX750 preclinical data to be presented at World Sleep Congress in October 2023Nominates second LockBody candidate, LB206, a conditionally bivalent PD-L1xCD3 bispecific monoclonal antibodyBOSTON and LONDON, Aug. 14, 2023 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today reported financial results and...

Company received Complete Response Letter from FDA for avasopasem and intends to request Type A meeting with FDA to discuss potential next steps Cash runway extended into Q2 2024 in connection with reduction in workforce FDA granted orphan drug designation to rucosopasem for the treatment of pancreatic cancer Enrollment in GRECO trials with rucosopasem remains ongoing MALVERN, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the second quarter ended June 30, 2023, and provided recent corporate updates. “Following the FDA’s decision on the avasopasem NDA, we have taken...

ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical trial anticipated in 2024 ITIL-306 operational in Manchester, UK manufacturing facility with additional process improvements DALLAS, Aug. 14, 2023 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported its second quarter 2023 financial results and provided a corporate update. “Successful manufacturing of ITIL-306 in our Manchester, UK facility is a major milestone on our path to clinical development of ITIL-306,” said Mark Dudley, Chief Scientific Officer of Instil Bio. “We have implemented improvements...

Omaha, Aug. 14, 2023 (GLOBE NEWSWIRE) — FitLife Brands, Inc. (“FitLife” or the “Company”) (OTC Pink: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the second quarter ended June 30, 2023, the first full quarter following the acquisition of Mimi’s Rock Corp (“MRC”) on February 28, 2023. Highlights for the second quarter ended June 30, 2023 include:Total revenue was $14.8 million, an increase of 89% compared to the second quarter of 2022.  Adjusted EBITDA was $3.0 million, an increase of 35% compared to the second quarter of 2022, approximately half of which was contributed by MRC. Net income for the second quarter of 2023 was $2.0 million compared to $1.4 million during the same period last year, an increase of 36%. Basic earnings per share increased...

For the three months ended June 30, 2023:Revenues of $793.0 million GAAP net income of $28.3 million Adjusted EBITDA of $72.5 million GAAP and adjusted earnings per share of $0.32 and $0.52, respectivelyProvides full-year financial outlookDURHAM, N.C., Aug. 14, 2023 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today reported financial results for the second quarter ended June 30, 2023. “Fortrea is now an independent CRO, as we successfully completed our spin at the end of June. This independence will allow Fortrea to focus our investments to improve research and delight our customers,” said Tom Pike, chairman and chief executive officer of Fortrea. “This is the next chapter for a company that has been carefully assembled over the past 30 years. We have...